# Risk Clustering and Stratification in Genetically High-Risk Individuals Using Electronic Medical Records and Biomarkers > **NIH NIH K23** · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2020 · $189,514 ## Abstract PROJECT SUMMARY/ABSTRACT This is a revised submission for a K23 award by Dr. Girish Nadkarni at the Icahn School of Medicine at Mount Sinai. Dr. Nadkarni is establishing himself as a young investigator in patient oriented clinical research of chronic kidney disease. This project will try to improve risk prediction and stratification for kidney disease progression in minority populations at baseline high genetic risk due to Apolipoprotein1 (APOL1) variants. Candidate: The primary objective of this application is to support Dr. Girish Nadkarni's career development into an independent investigator in the field of leveraging biomarkers, genomics and “big data” approaches for renal research. Dr. Nadkarni's career goal is to accurately risk stratify patients for renal functional decline for future targeted enrolment into clinical trials evaluating novel interventions. To achieve these goals, Dr. Nadkarni has assembled a mentoring and advisory team led by a primary mentor, Dr. Steven Coca, Associate Professor and Director of Clinical Research at the Icahn School of Medicine at Mount Sinai, and a co-mentor Dr. Erwin Bottinger, Professor of Medicine and former Director of The Charles Bronfman Institute of Personalized Medicine. His advisory team consists of Dr. Emilia Bagiella, Professor in the Division of Biostatistics at Mount Sinai and an expert in longitudinal analysis; Dr. Eimear Kenny, Assistant Professor in the Department of Genetics and Genomics and an expert in statistical and population genetics; Dr. Avi Ma'ayan, an Associate Professor in the Department of Pharmacology and Systems Therapeutics and an expert in bioinformatics and Dr. Judy Cho, the incoming director of the Charles Bronfman Institute of Personalized Medicine and an expert in translational genetics. His proposed training plan focuses on four areas (1) Advanced Statistical and Epidemiological Methodology; (2) Biomarker Methodology; (3) Computational Bioinformatics and Programming and (4) Focused mentorship and career development. Environment: Icahn School of Medicine at Mount Sinai is a national leader in research and is one of the top 20 medical schools in NIH funding. ISMMS was also named as one of the "The World's Top 10 Most Innovative Companies In Big Data" due to its computing resources and the BioMe Biobank, whose primary architect is Dr.Bottinger and is currently led by Dr. Cho. Research: Ethnic minorities are at higher risk of both development and progression of chronic kidney disease. This has been linked in part to risk variants in the APOL1 gene that are present in up to 14% in populations of African descent (including African Americans [AAs] and Hispanic Latinos [HLas]) but are absent in non- Hispanic Whites. Although APOL1 high-risk genotype is, in general, associated with faster eGFR decline, only about 50% progress to ESRD and patients within this group have differing rates of renal functional decline. Thus, risk stratification within this group is poor, limiting earl... ## Key facts - **NIH application ID:** 9937700 - **Project number:** 5K23DK107908-05 - **Recipient organization:** ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI - **Principal Investigator:** Girish Nitin Nadkarni - **Activity code:** K23 (R01, R21, SBIR, etc.) - **Funding institute:** NIH - **Fiscal year:** 2020 - **Award amount:** $189,514 - **Award type:** 5 - **Project period:** 2016-08-15 → 2021-05-31 ## Primary source NIH RePORTER: https://reporter.nih.gov/project-details/9937700 ## Citation > US National Institutes of Health, RePORTER application 9937700, Risk Clustering and Stratification in Genetically High-Risk Individuals Using Electronic Medical Records and Biomarkers (5K23DK107908-05). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/9937700. Licensed CC0. --- *[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*